Skip to main content
PMC home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 2001 Jan;26(1):55–59.

Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.

A Khullar 1, P Chue 1, P Tibbo 1
PMCID: PMC1408029  PMID: 11212595

Abstract

The atypical antipsychotics have advanced the treatment of schizophrenia and have proved to be effective agents in treating other disorders with or without psychotic features. We review the literature concerning an increasingly reported and interesting adverse effect, atypical antipsychotic-induced obsessive-compulsive symptoms (OCS). The first known report of quetiapine exacerbating OCS in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented. Mechanisms, including 5-HT2A and 5-HT2C antagonism, serotonergic regulation of dopamine systems and putative dopaminergic subtypes of OCS and OCD, are discussed. Given the paradoxical efficacy of the atypical antipsychotics in pure OCD, the neurobiology and comorbidity of OCD and schizophrenia, as well as the increasing use of atypical antipsychotics, a cautious and rational pharmacotherapeutic treatment approach is recommended.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abi-Dargham A., Laruelle M., Aghajanian G. K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci. 1997 Winter;9(1):1–17. doi: 10.1176/jnp.9.1.1. [DOI] [PubMed] [Google Scholar]
  2. Andrade C. Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry. 1998 May;59(5):255–256. doi: 10.4088/jcp.v59n0509c. [DOI] [PubMed] [Google Scholar]
  3. Baker R. W., Ames D., Umbricht D. S., Chengappa K. N., Schooler N. R. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull. 1996;32(1):89–93. [PubMed] [Google Scholar]
  4. Baker R. W., Chengappa K. N., Baird J. W., Steingard S., Christ M. A., Schooler N. R. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992 Dec;53(12):439–442. [PubMed] [Google Scholar]
  5. Buckley P. F., Sajatovic M., Meltzer H. Y. Treatment of delusional disorders with clozapine. Am J Psychiatry. 1994 Sep;151(9):1394–1395. doi: 10.1176/ajp.151.9.1394. [DOI] [PubMed] [Google Scholar]
  6. Dewey S. L., Smith G. S., Logan J., Alexoff D., Ding Y. S., King P., Pappas N., Brodie J. D., Ashby C. R., Jr Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995 Jan;15(1 Pt 2):821–829. doi: 10.1523/JNEUROSCI.15-01-00821.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Duinkerke S. J., Botter P. A., Jansen A. A., van Dongen P. A., van Haaften A. J., Boom A. J., van Laarhoven J. H., Busard H. L. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry. 1993 Oct;163:451–455. doi: 10.1192/bjp.163.4.451. [DOI] [PubMed] [Google Scholar]
  8. Dursun S. M., Reveley M. A. Obsessive-compulsive symptoms and clozapine. Br J Psychiatry. 1994 Aug;165(2):267–268. doi: 10.1192/bjp.165.2.267. [DOI] [PubMed] [Google Scholar]
  9. Ghaemi S. N., Zarate C. A., Jr, Popli A. P., Pillay S. S., Cole J. O. Is there a relationship between clozapine and obsessive-compulsive disorder?: a retrospective chart review. Compr Psychiatry. 1995 Jul-Aug;36(4):267–270. doi: 10.1016/s0010-440x(95)90071-3. [DOI] [PubMed] [Google Scholar]
  10. Levkovitch Y., Kronnenberg Y., Gaoni B. Can clozapine trigger OCD? J Am Acad Child Adolesc Psychiatry. 1995 Mar;34(3):263–263. doi: 10.1097/00004583-199503000-00005. [DOI] [PubMed] [Google Scholar]
  11. McDougle C. J., Fleischmann R. L., Epperson C. N., Wasylink S., Leckman J. F., Price L. H. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1995 Nov;56(11):526–528. [PubMed] [Google Scholar]
  12. McDougle C. J., Goodman W. K., Leckman J. F., Lee N. C., Heninger G. R., Price L. H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr;51(4):302–308. doi: 10.1001/archpsyc.1994.03950040046006. [DOI] [PubMed] [Google Scholar]
  13. McDougle C. J., Goodman W. K., Leckman J. F., Price L. H. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am. 1993 Dec;16(4):749–766. [PubMed] [Google Scholar]
  14. McDougle C. J., Goodman W. K., Price L. H., Delgado P. L., Krystal J. H., Charney D. S., Heninger G. R. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990 May;147(5):652–654. doi: 10.1176/ajp.147.5.652. [DOI] [PubMed] [Google Scholar]
  15. Meltzer H. Y., Matsubara S., Lee J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989 Oct;251(1):238–246. [PubMed] [Google Scholar]
  16. Morrison D., Clark D., Goldfarb E., McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry. 1998 Jun;155(6):855–855. doi: 10.1176/ajp.155.6.855. [DOI] [PubMed] [Google Scholar]
  17. Mottard J. P., de la Sablonnière J. F. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry. 1999 May;156(5):799–800. doi: 10.1176/ajp.156.5.799. [DOI] [PubMed] [Google Scholar]
  18. Patil V. J. Development of transient obsessive-compulsive symptoms during treatment with clozapine. Am J Psychiatry. 1992 Feb;149(2):272–272. doi: 10.1176/ajp.149.2.272a. [DOI] [PubMed] [Google Scholar]
  19. Pitman R. K., Green R. C., Jenike M. A., Mesulam M. M. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry. 1987 Sep;144(9):1166–1171. doi: 10.1176/ajp.144.9.1166. [DOI] [PubMed] [Google Scholar]
  20. Reynolds G. P. What is an atypical antipsychotic? J Psychopharmacol. 1997;11(3):195–199. doi: 10.1177/026988119701100301. [DOI] [PubMed] [Google Scholar]
  21. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60 (Suppl 10):5–14. [PubMed] [Google Scholar]
  22. Saxena S., Wang D., Bystritsky A., Baxter L. R., Jr Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996 Jul;57(7):303–306. [PubMed] [Google Scholar]
  23. Schotte A., Janssen P. F., Gommeren W., Luyten W. H., Van Gompel P., Lesage A. S., De Loore K., Leysen J. E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996 Mar;124(1-2):57–73. doi: 10.1007/BF02245606. [DOI] [PubMed] [Google Scholar]
  24. Tibbo P., Warneke L. Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. J Psychiatry Neurosci. 1999 Jan;24(1):15–24. [PMC free article] [PubMed] [Google Scholar]
  25. Toren P., Samuel E., Weizman R., Golomb A., Eldar S., Laor N. Case study: emergence of transient compulsive symptoms during treatment with clothiapine. J Am Acad Child Adolesc Psychiatry. 1995 Nov;34(11):1469–1472. [PubMed] [Google Scholar]
  26. Zald D. H., Kim S. W. Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry; and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):125–138. doi: 10.1176/jnp.8.2.125. [DOI] [PubMed] [Google Scholar]
  27. al-Mulhim A., Atwal S., Coupland N. J. Provocation of obsessive-compulsive behaviour and tremor by olanzapine. Can J Psychiatry. 1998 Aug;43(6):645–645. [PubMed] [Google Scholar]
  28. de Haan L., Linszen D. H., Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999 Jun;60(6):364–365. doi: 10.4088/jcp.v60n0603. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES